AstraZeneca Boosts Rare Disease Pipeline With Ionis Antisense Candidate
Pays $200m Upfront
Executive Summary
AstraZeneca has bulked up its late-stage pipeline with an agreement for Ionis’s eplontersen which is in trials for two rare diseases, quelling some analysts’ fears about the scarcity of catalysts for next year.
You may also be interested in...
Deal Watch: Novartis, Ionis Team Up Again In Cardiovascular Disease
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
AstraZeneca And Ionis ATTR Ambitions Boosted
The companies are hoping that new data on recently-filed eplontersen will boost the drug's chances of challenging Alnylam’s Amvuttra and Onpattro.
In Vivo’s Deals Of The Year 2021: Cast Your Vote!
It is time for In Vivo's 14th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.